Abstract
Mobility limitations, which affect the majority of individuals living with multiple sclerosis (MS), are frequently addressed by clinicians and researchers, as they are at the heart of patients' (and families') concerns at the time of diagnosis and throughout the course of the disease. Ambulation, one of the key components of mobility, is routinely assessed through patient report, direct observation, and standardized tests and scales to monitor the progression of MS and the efficacy of disease-modifying therapies. Mobility-related issues can be a major source of frustration for patients, families, and health-care providers given the progressive nature of the disease, its heterogeneity, and its unpredictability. However, the recent growth in the body of evidence for the assessment and management of mobility restrictions, and in the spectrum of interventions available, brings renewed energy and hope.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
